{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:41:08Z","timestamp":1792726868610,"version":"4.5.0"},"reference-count":25,"publisher":"e-Century Publishing Corporation","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/uuck9838","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:31:51Z","timestamp":1767148311000},"page":"9667-9676","source":"Crossref","is-referenced-by-count":1,"title":["Entecavir provides favorable virological control but minimal metabolic benefit in patients with Chronic Hepatitis B and MAFLD"],"prefix":"10.62347","volume":"17","author":[{"given":"Baojian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.2147\/DMSO.S369824","article-title":"Association between metabolic dysfunction-associated fatty liver disease and the risk of cirrhosis in patients with Chronic Hepatitis B-a retrospective cohort study","volume":"15","author":"Wang","year":"2022","unstructured":"Wang QX, Xue J, Shi MJ, Xie YB, Xiao HM, Li S, Lin M and Chi XL. Association between metabolic dysfunction-associated fatty liver disease and the risk of cirrhosis in patients with Chronic Hepatitis B-a retrospective cohort study. Diabetes Metab Syndr Obes 2022; 15: 2311-2322.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/hepr.13830","article-title":"Effect of metabolic dysfunction-associated fatty liver disease on liver cancer risk in a population with Chronic Hepatitis B virus infection: a nationwide study","volume":"52","author":"Yun","year":"2022","unstructured":"Yun B, Ahn SH, Oh J, Yoon JH and Kim BK. Effect of metabolic dysfunction-associated fatty liver disease on liver cancer risk in a population with Chronic Hepatitis B virus infection: a nationwide study. Hepatol Res 2022; 52: 975-984.","journal-title":"Hepatol Res"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3350\/cmh.2022.0422","article-title":"Chronic Hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: challenges and perspectives","volume":"29","author":"Huang","year":"2023","unstructured":"Huang SC and Liu CJ. Chronic Hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: challenges and perspectives. Clin Mol Hepatol 2023; 29: 320-331.","journal-title":"Clin Mol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1016\/j.jfma.2022.07.013","article-title":"Metabolic dysfunction-associated fatty liver disease and Chronic Hepatitis B","volume":"121","author":"Huang","year":"2022","unstructured":"Huang SC and Kao JH. Metabolic dysfunction-associated fatty liver disease and Chronic Hepatitis B. J Formos Med Assoc 2022; 121: 2148-2151.","journal-title":"J Formos Med Assoc"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"100350","DOI":"10.1016\/j.jhepr.2021.100350","article-title":"Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with Chronic Hepatitis B","volume":"3","author":"van Kleef","year":"2021","unstructured":"van Kleef LA, Choi HSJ, Brouwer WP, Hansen BE, Patel K, de Man RA, Janssen HLA, de Knegt RJ and Sonneveld MJ. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with Chronic Hepatitis B. JHEP Rep 2021; 3: 100350.","journal-title":"JHEP Rep"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.jhep.2022.07.018","article-title":"Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with Chronic Hepatitis B","volume":"77","author":"Ji","year":"2022","unstructured":"Ji D, Chen Y, Bi J, Shang Q, Liu H, Wang JB, Tan L, Wang J, Chen Y, Li Q, Long Q, Song L, Jiang L, Xiao G, Yu Z, Chen L, Wang X, Chen D, Li Z, Dong Z and Yang Y. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with Chronic Hepatitis B. J Hepatol 2022; 77: 1515-1524.","journal-title":"J Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"21656","DOI":"10.1038\/s41598-024-72986-9","article-title":"Real-world study on the efficacy and safety of different treatment regimens in treatment-naïve CHB patients with high viral load","volume":"14","author":"Wu","year":"2024","unstructured":"Wu X, Yan Q, Jiang C, Fan R and Li S. Real-world study on the efficacy and safety of different treatment regimens in treatment-naïve CHB patients with high viral load. Sci Rep 2024; 14: 21656.","journal-title":"Sci Rep"},{"key":"ref7","unstructured":"Chinese Medical Association; Chinese Medical Journals Publishing House; Chinese Society of General Practice; Editorial Board of Chinese Journal of Ceneral; Practitioners of Chinese Medical Association and Expert Group of Guidelines for Primary Care of Chronic Hepatitis B. Guideline for primary care of Chronic Hepatitis B: practice version (2020). Chin Gen Pract 2021; 20: 281-289."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s12072-024-10774-3","article-title":"The Asian pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease","volume":"19","author":"Eslam","year":"2025","unstructured":"Eslam M, Fan JG, Yu ML, Wong VW, Cua IH, Liu CJ, Tanwandee T, Gani R, Seto WK, Alam S, Young DY, Hamid S, Zheng MH, Kawaguchi T, Chan WK, Payawal D, Tan SS, Goh GB, Strasser SI, Viet HD, Kao JH, Kim W, Kim SU, Keating SE, Yilmaz Y, Kamani L, Wang CC, Fouad Y, Abbas Z, Treeprasertsuk S, Thanapirom K, Al Mahtab M, Lkhagvaa U, Baatarkhuu O, Choudhury AK, Stedman CAM, Chowdhury A, Dokmeci AK, Wang FS, Lin HC, Huang JF, Howell J, Jia J, Alboraie M, Roberts SK, Yoneda M, Ghazinian H, Mirijanyan A, Nan Y, Lesmana CRA, Adams LA, Shiha G, Kumar M, Örmeci N, Wei L, Lau G, Omata M, Sarin SK and George J. The Asian pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease. Hepatol Int 2025; 19: 261-301.","journal-title":"Hepatol Int"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1002\/mp.16700","article-title":"TMM: a comprehensive CAD system for hepatic fibrosis 5-grade METAVIR staging based on liver MRI","volume":"51","author":"Liu","year":"2024","unstructured":"Liu H, Fu Y, Guo D, Li S, Jin Y, Zhang A and Wu C. TMM: a comprehensive CAD system for hepatic fibrosis 5-grade METAVIR staging based on liver MRI. Med Phys 2024; 51: 2032-2043.","journal-title":"Med Phys"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of Chronic Hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH and Wong JB. Update on prevention, diagnosis, and treatment of Chronic Hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67: 1560-1599.","journal-title":"Hepatology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"783339","DOI":"10.3389\/fonc.2021.783339","article-title":"Outcomes of liver resection for metabolic dysfunction-associated fatty liver disease or Chronic Hepatitis B-related HCC","volume":"11","author":"Liu","year":"2022","unstructured":"Liu L, Xie S, Teng YX, Deng ZJ, Chen K, Liu HT, Huo RR, Liang XM, Guo PP, Yang DL, Ma L, Xiang BD, Li LQ and Zhong JH. Outcomes of liver resection for metabolic dysfunction-associated fatty liver disease or Chronic Hepatitis B-related HCC. Front Oncol 2022; 11: 783339.","journal-title":"Front Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2420858","DOI":"10.1080\/07853890.2024.2420858","article-title":"Diagnostic accuracy of FibroScan-AST (FAST) score, non-alcoholic fatty liver fibrosis score (NFS), FibroScan, and liver fibrosis index (FIB-4) for identifying fibrotic non-alcoholic steatohepatitis in patients with Chronic Hepatitis B with metabolic dysfunction-associated fatty liver disease","volume":"56","author":"Tan","year":"2024","unstructured":"Tan Y and Zhang X. Diagnostic accuracy of FibroScan-AST (FAST) score, non-alcoholic fatty liver fibrosis score (NFS), FibroScan, and liver fibrosis index (FIB-4) for identifying fibrotic non-alcoholic steatohepatitis in patients with Chronic Hepatitis B with metabolic dysfunction-associated fatty liver disease. Ann Med 2024; 56: 2420858.","journal-title":"Ann Med"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Huang SC, Su TH, Tseng TC, Chen CL, Hsu SJ, Liu CH, Liao SH, Hong CM, Lan TY, Yang HC, Liu CJ, Chen PJ and Kao JH. Metabolic dysfunction-associated steatotic liver disease facilitates hepatitis B surface antigen seroclearance and seroconversion. Clin Gastroenterol Hepatol 2024; 22: 581-590, e6.","DOI":"10.1016\/j.cgh.2023.09.040"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.3390\/v15112241","article-title":"Lamivudine and entecavir for acute hepatitis B: a systematic review and meta-analysis","volume":"15","author":"Henriquez-Camacho","year":"2023","unstructured":"Henriquez-Camacho C, Hijas-Gomez AI, Risco Risco C, Ruiz Lapuente MA, Escudero-Sanchez R and Cuerda VM. Lamivudine and entecavir for acute hepatitis B: a systematic review and meta-analysis. Viruses 2023; 15: 2241.","journal-title":"Viruses"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4725","DOI":"10.1016\/j.asjsur.2024.03.147","article-title":"Effect of tenofovir versus entecavir on the long-term prognosis in hepatocellular carcinoma patients with concurrent metabolic dysfunction-associated steatotic liver disease and hepatitis B","volume":"47","author":"Kong","year":"2024","unstructured":"Kong Q, Gao Q, Li W and Chen Z. Effect of tenofovir versus entecavir on the long-term prognosis in hepatocellular carcinoma patients with concurrent metabolic dysfunction-associated steatotic liver disease and hepatitis B. Asian J Surg 2024; 47: 4725-4734.","journal-title":"Asian J Surg"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.3390\/biomedicines10112824","article-title":"Baseline circulating mir-125b levels predict a high FIB-4 index score in Chronic Hepatitis B patients after nucleos(t)ide analog treatment","volume":"10","author":"JY","year":"2022","unstructured":"Wu JY, Tsai YS, Li CC, Yeh ML, Huang CI, Huang CF, Hsu JN, Hsieh MH, Chen YC, Liu TW, Lin YH, Liang PC, Lin ZY, Chuang WL, Yu ML and Dai CY. Baseline circulating mir-125b levels predict a high FIB-4 index score in Chronic Hepatitis B patients after nucleos(t)ide analog treatment. Biomedicines 2022; 10: 2824.","journal-title":"Biomedicines"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.3390\/v14122668","article-title":"Clinical outcomes and quantitative HBV surface antigen levels in diverse Chronic Hepatitis B patients in Canada: a retrospective real-world study of CHB in Canada (Reveal-Canada)","volume":"14","author":"Coffin","year":"2022","unstructured":"Coffin CS, Haylock-Jacobs S, Doucette K, Ramji A, Ko HH, Wong DK, Elkhashab M, Bailey R, Uhanova J, Minuk G, Tsoi K, Wong A, Ma MM, Tam E, Brahmania M, Nudo C, Zhu J, Lowe CF, Osiowy C, Lethebe BC, Congly SE, Chan EKH, Villasis-Keever A, Sbarigia U, Cooper CL and Fung S. Clinical outcomes and quantitative HBV surface antigen levels in diverse Chronic Hepatitis B patients in Canada: a retrospective real-world study of CHB in Canada (Reveal-Canada). Viruses 2022; 14: 2668.","journal-title":"Viruses"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.3390\/cancers14236012","article-title":"Metabolic-associated fatty liver disease, Hepatitis B surface antigen seroclearance, and long-term risk of hepatocellular carcinoma in Chronic Hepatitis B","volume":"14","author":"MW","year":"2022","unstructured":"Yu MW, Lin CL, Liu CJ, Wu WJ, Hu JT and Huang YW. Metabolic-associated fatty liver disease, Hepatitis B surface antigen seroclearance, and long-term risk of hepatocellular carcinoma in Chronic Hepatitis B. Cancers (Basel) 2022; 14: 6012.","journal-title":"Cancers (Basel)"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.4254\/wjh.v14.i8.1652","article-title":"Metabolic-associated fatty liver disease is associated with low muscle mass and strength in patients with Chronic Hepatitis B","volume":"14","author":"Santos","year":"2022","unstructured":"Santos CML, Brito MD, de Castro PASV, de Vries TP, Viana NL, Coelho MPP, Malheiro OB, Bering T, Gonzalez MC, Teixeira R, Cambraia RD, Rocha GA and Silva LD. Metabolic-associated fatty liver disease is associated with low muscle mass and strength in patients with Chronic Hepatitis B. World J Hepatol 2022; 14: 1652-1666.","journal-title":"World J Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s40121-022-00725-6","article-title":"Metabolic syndrome, nonalcoholic fatty liver disease, and Chronic Hepatitis B: a narrative review","volume":"12","author":"Diao","year":"2023","unstructured":"Diao Y, Tang J, Wang X, Deng W, Tang J and You C. Metabolic syndrome, nonalcoholic fatty liver disease, and Chronic Hepatitis B: a narrative review. Infect Dis Ther 2023; 12: 53-66.","journal-title":"Infect Dis Ther"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"101957","DOI":"10.1016\/j.clinre.2022.101957","article-title":"Hepatic steatosis leads to overestimation of liver stiffness measurement in both Chronic Hepatitis B and metabolic-associated fatty liver disease patients","volume":"46","author":"Liu","year":"2022","unstructured":"Liu J, Ma Y, Han P, Wang J, Liu YG, Shi RF and Li J. Hepatic steatosis leads to overestimation of liver stiffness measurement in both Chronic Hepatitis B and metabolic-associated fatty liver disease patients. Clin Res Hepatol Gastroenterol 2022; 46: 101957.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Patmore LA, van Eekhout K, Koc ÖM, de Knegt RJ, Janssen HLA, Brouwer WP, Kramer M, Honkoop P, de Bruijne J, Boland GJ, Postma DF, Blokzijl H, de Man RA, Takkenberg RB and Sonneveld MJ. The association between metabolic dysfunction-associated steatotic liver disease and change in liver stiffness in patients with Chronic Hepatitis B. Liver Int 2025; 45: e70042.","DOI":"10.1111\/liv.70042"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1007\/s10620-024-08354-4","article-title":"Effect of concurrent metabolic dysfunction-associated steatotic liver disease on serial non-invasive fibrosis markers in Chronic Hepatitis B","volume":"69","author":"Con","year":"2024","unstructured":"Con D, Tu S, Clayton-Chubb D, Lubel JS, Nicoll AJ, Sawhney R and Bloom S. Effect of concurrent metabolic dysfunction-associated steatotic liver disease on serial non-invasive fibrosis markers in Chronic Hepatitis B. Dig Dis Sci 2024; 69: 1496-1506.","journal-title":"Dig Dis Sci"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.jhep.2022.07.037","article-title":"Validation of baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis","volume":"77","author":"Wang","year":"2022","unstructured":"Wang Q, Zhao H, Deng Y, Zheng H, Xiang H, Nan Y, Hu J, Meng Q, Xu X, Fang J, Xu J, Wang X, You H, Pan CQ, Xie W and Jia J. Validation of baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis. J Hepatol 2022; 77: 1564-1572.","journal-title":"J Hepatol"}],"container-title":["American Journal of Translational Research"],"original-title":[],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:34:59Z","timestamp":1792726499000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/12\/ajtr0167859.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":25,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/uuck9838","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}